Aeterna's test for adult growth hormone deficiency reaches goal in PhIII study
This article was originally published in Scrip
Executive Summary
Aeterna Zentaris has reported that AEZS-130, the company's novel synthetic molecule that stimulates the secretion of growth hormones, reached its primary endpoint of more than 90% sensitivity and specificity in a Phase III study as a simple oral diagnostic test for adult growth hormone deficiency (AGHD).